Genentech profit rises, sales top estimates

NEW YORK (Reuters) - Genentech Inc reported on Tuesday that sales of its cancer drug Avastin topped Wall Street estimates and its shares rose more than 3 percent, despite third-quarter earnings that fell short of analyst expectations due to higher costs.

Read The Full Story

Share: Digg - del.icio.us - Stumble It - News Vine - buzz-it

Source: Reuters Published: Tuesday 14th of October 2008

Members: Save This Story